| 1. |
|
|
| 2. |
|
|
| 3. |
- Bock, O., et al.
(author)
-
Use of GNSS Tropospheric Products for Climate Monitoring (Working Group 3)
- 2020
-
In: Advanced GNSS Tropospheric Products for Monitoring Severe Weather Events and Climate. - Cham : Springer International Publishing. - 9783030139001 ; , s. 267-402
-
Book chapter (other academic/artistic)abstract
- There has been growing interest in recent years in the use of homogeneously reprocessed ground-based GNSS, VLBI, and DORIS measurements for climate applications. Existing datasets are reviewed and the sensitivity of tropospheric estimates to the processing details is discussed. The uncertainty in the derived IWV estimates and linear trends is around 1 kg m^2 RMS and ± 0.3 kg m^2 per decade, respectively. Standardized methods for ZTD outlier detection and IWV conversion are proposed. The homogeneity of final time series is limited however by changes in the stations equipment and environment. Various homogenization algorithms have been evaluated based on a synthetic benchmark dataset. The uncertainty of trends estimated from the homogenized times series is estimated to ±0.5 kg m^2 per decade. Reprocessed GNSS IWV data are analysed along with satellites data, reanalyses and global and regional climate model simulations. A selection of global and regional reprocessed GNSS datasets and ERA-interim reanalysis are made available through the GOP-TropDB tropospheric database and online service. A new tropo SINEX format, providing new features and simplifications, was developed and it is going to be adopted by all the IAG services.
|
|
| 4. |
|
|
| 5. |
- Robbe, P, et al.
(author)
-
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
- 2022
-
In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 54:11, s. 1675-
-
Journal article (peer-reviewed)abstract
- The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled in clinical trials as part of the United Kingdom’s 100,000 Genomes Project. We identify an extended catalog of recurrent coding and noncoding genetic mutations that represents a source for future studies and provide the most complete high-resolution map of structural variants, copy number changes and global genome features including telomere length, mutational signatures and genomic complexity. We demonstrate the relationship of these features with clinical outcome and show that integration of 186 distinct recurrent genomic alterations defines five genomic subgroups that associate with response to therapy, refining conventional outcome prediction. While requiring independent validation, our findings highlight the potential of whole-genome sequencing to inform future risk stratification in chronic lymphocytic leukemia.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Khoury, J. D., et al.
(author)
-
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- 2022
-
In: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 36, s. 1703-1719
-
Journal article (peer-reviewed)abstract
- The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.
|
|
| 9. |
|
|
| 10. |
|
|
